Health Care & Life Sciences » Pharmaceuticals | Neos Therapeutics Inc.

Neos Therapeutics Inc.

Neos Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.33
Market Cap
$71.1 M
Shares Outstanding
49.72 M
Public Float
42.9 M

Profile

Address
2940 North Highway 360
Grand Prairie Texas 75050
United States
Employees -
Website http://www.neostx.com
Updated 07/08/2019
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold.

Financials

View All

Gerald W. McLaughlin
President, Chief Executive Officer & Director
Alan L. Heller
Chairman